This drug also decreases β-catenin expression and its downstream targets c-Myc and cyclin D1, increases the LATS1 protein level and phosphorylation level of Yes-associated protein (YAP) at Ser127 and decreases the CYR61 levels, suggesting that simvastatin is able to inhibit YAP and β-catenin activity in GC cells [65]. Here, MYC is linked to gastric cancer.